PSP Research LLC Portfolio

Auto-discovered active 13F filer.

SEC 13F CIK: 0002106939

What is a 13F filing? Who files one and when · What 13F filings can't tell you

SmallFocusedHigh Turnover how tags are computed

Q3 2026 Q2 2026 Q1 2026 Q4 2025

Q3 2026 · 44 positions · Total reported value $145.83M · Top-10 concentration 95.0% · Updated 2026-10-21

Last updated: 2026-10-21 · Source: SEC EDGAR Form 13F-HR

Turnover: 78.9% · 1 new · 27 cut · 32 exited

Active Share (vs S&P 500): 100.0% · vs QQQ: 100.0% — share of the book that differs from index weights (higher = more active) · ranking

Est. Qtr Return (Q2 2026 → Q3 2026): -1.5% · vs SPY -3.6% · Prev Value $187.88M — last quarter positions weighted by this quarter price moves · ranking

Est. QTD Return (Q3 2026 → newest close): -0.5% · vs SPY -2.6% · Latest Value $145.83M — latest reported positions valued at quarter-to-date price moves (still in progress) · ranking

In its Q3 2026 13F filing, PSP Research LLC disclosed 44 equity positions with a combined reported value of $145.83M. The filing implies a focused portfolio: its ten largest positions account for 95.0% of reported value. HoldingsHub classifies the profile as Small / Focused / High Turnover.

The largest disclosed positions as of Q3 2026 were SGOV ($70.48M), XBI ($60.94M), SERA ($5.01M). By sector, the heaviest allocations are Health Care 9.9%, Other 90.1%. Versus the prior quarter, allocation shifted toward Other (+4.4pp) and away from Health Care (-4.3pp).

Versus the prior quarter, PSP Research LLC opened 1 new positions, trimmed 27 and fully exited 32, a turnover rate of 78.9% of positions. The portfolio's overlap with the prior quarter was 57% of names.

The largest new positions opened in Q3 2026 were SERA ($5.01M).

Of the 32 positions fully exited versus the prior quarter, the largest were IRON ($585.12K), RAPP ($583.38K), RARE ($567.63K).

Figures come from the fund's SEC Form 13F filing. 13F reports are filed within 45 days of quarter end and cover long positions of $100,000 or more; they exclude short positions and non-13F asset classes, so treat this page as a quarter-end snapshot rather than the fund's live book.

New Positions (Q3 2026)

  • SERA SERA PROGNOSTICS INC · $5.01M

Fully Exited (vs previous quarter)

  • IRON DISC MEDICINE INC · prev qtr: $585.12K
  • RAPP RAPPORT THERAPEUTICS INC COM · prev qtr: $583.38K
  • RARE ULTRAGENYX PHARMACEUTICAL IN · prev qtr: $567.63K
  • GLUE MONTE ROSA THERAPEUTICS INC · prev qtr: $556.60K
  • IONS IONIS PHARMACEUTICALS IN · prev qtr: $539.17K
  • PHVS PHARVARIS NV · prev qtr: $518.70K
  • ACAD ACADIA PHARMACEUTICALS INC · prev qtr: $500.08K
  • PTCT PTC THERAPEUTICS INC · prev qtr: $489.42K

Insider Transactions (Form 4)

Latest PSP Research LLC buys and sells reported on SEC Form 4 — filed within two business days when the fund's ownership in a stock crosses 10%.

No Form 4 filings for this fund yet — when its ownership in a stock crosses 10%, buys and sells are filed here within two business days.

Fund Profile

PSP Research LLC files quarterly US equity holdings with the SEC on Form 13F. Its latest filing (Q3 2026) lists 44 positions worth $145.83M in total. HoldingsHub carries 4 quarters of its filings (Q4 2025–Q3 2026).

Firm Snapshot

  • SEC registration: 801-131402 (status: Approved), registered 2024-11-04
  • Regulatory AUM (Form ADV): $178.64M as of 2026-07-01

Portfolio Structure

  • 44 positions · $145.83M reported value (Q3 2026)
  • Top 10 holdings = 95.0% of reported value
  • Largest position: SGOV (ISHARES TR) at 48.3%
  • Average position size: $3.31M

Sector Tilt

  • Health Care 9.9%
  • (classified holdings cover 10% of value)

Quarterly Activity

  • Q3 2026: 1 new, 27 reduced, 32 exited
  • 16 positions unchanged

Generated from the firm's public SEC Form 13F and ADV filings. It states what the firm has reported — not an evaluation of its strategy, and not investment advice.

AI Rebalance Analysis

1. Overall Direction and Market View: The fund appears to maintain a cautious stance with a focus on stability, as indicated by the "Hold" action on the majority of its positions and a reduction in some high-risk or volatile sectors. 2. Key Moves: - Added: SERA (SERA Prognostics Inc.) was added to the portfolio, indicating a potential interest in the healthcare sector. - Reduced: The fund reduced its holdings in XBI (SPDR Biotech ETF), HALO (Halozyme Therapeutics Inc.), EXEL (Exelixis Inc.), RPRX (Royalty Pharma PLC), ARGX (Argenx SE), NRIX (Nurix Therapeutics Inc.), and TGTX (TG Therapeutics Inc.), reflecting a move away from these sectors or companies. - Hold: The fund held its positions in SGOV (iShares 0-3 Mth Treasury BD ETF) and MDGL (Madrugal Pharmaceuticals Inc.), suggesting a preference for these sectors or companies. 3. Portfolio Structure: - Passive/Active: The portfolio seems to be leaning towards passive management, given the high allocation to ETFs like SGOV and XBI. - Sector Bias: The portfolio has a strong bias towards the healthcare sector, with 7 out of 10 top holdings in this sector. - Risk Appetite: The risk appetite is conservative, as evidenced by the "Hold" and "Reduce" actions and the significant reduction in positions in high-risk sectors. 4. Per-Holding One-Liner: - SGOV (ISHS): iShares 0-3 Mth Treasury Bond ETF - A passively managed ETF that tracks the performance of U.S. Treasury bonds with maturities of 0-3 years. - XBI (SPDR): SPDR Biotech ETF - An ETF that seeks to provide investment results that correspond to the performance of an index composed of U.S. biotechnology companies. - SERA (SERA Prognostics Inc.): SERA Prognostics Inc. - A healthcare company focused on the development of diagnostics for kidney disease. - HALO (Halozyme Therapeutics Inc.): Halozyme Therapeutics Inc. - A biotechnology company developing enzyme replacement therapies for lysosomal storage disorders. - MDGL (Madrugal Pharmaceuticals Inc.): Madrugal Pharmaceuticals Inc. - A biotechnology company focused on developing novel therapies for cardiovascular and metabolic diseases. - EXEL (Exelixis Inc.): Exelixis Inc. - A biotechnology company that develops small molecule therapies for cancer. - RPRX (Royalty Pharma PLC): Royalty Pharma PLC - A healthcare company that acquires, builds, and manages royalty streams from innovative medicines. - ARGX (Argenx SE): Argenx SE - A biotechnology company focused on developing therapies for immune disorders. - NRIX (Nurix Therapeutics Inc.): Nurix Therapeutics Inc. - A biotechnology company developing small molecule drugs for the treatment of rare genetic disorders. - TGTX (TG Therapeutics Inc.): TG Therapeutics Inc. - A biotechnology company focused on the development of innovative therapies for the treatment of cancer. 5. One-Sentence Style Summary: PSP Research LLC maintained a conservative, sector-heavy approach in Q3 2026, focusing on stability through a mix of passive ETFs and selective healthcare investments.

Generated by GLM-4.5-flash from the latest 13F holdings and quarter-over-quarter changes. For reference only, not investment advice.

Sector Allocation

Other 90.1%
Sort by: Value Shares Weight Sector Change · CSV
# Shares Value Weight Allocation Change
1 700.00K $70.48M 48.33%
48.33%
Hold
2 386.50K $60.94M 41.79%
41.79%
Reduce
3 2.40M $5.01M 3.44%
3.44%
New
4 3.00K $331.20K 0.23%
0.23%
Reduce
5 600 $302.38K 0.21%
0.21%
Hold
6 5.00K $292.05K 0.20%
0.20%
Reduce
7 5.00K $291.80K 0.20%
0.20%
Reduce
8 300 $287.67K 0.20%
0.20%
Reduce
9 12.00K $284.52K 0.20%
0.20%
Reduce
10 5.00K $278.90K 0.19%
0.19%
Reduce
11 3.50K $275.13K 0.19%
0.19%
Reduce
12 7.00K $274.82K 0.19%
0.19%
Reduce
13 10.00K $264.30K 0.18%
0.18%
Reduce
14 3.50K $261.13K 0.18%
0.18%
Reduce
15 6.00K $258.24K 0.18%
0.18%
Hold
16 12.00K $258.12K 0.18%
0.18%
Reduce
17 1.80K $255.31K 0.17%
0.17%
Reduce
18 3.00K $249.87K 0.17%
0.17%
Hold
19 10.00K $249.50K 0.17%
0.17%
Hold
20 6.50K $247.39K 0.17%
0.17%
Reduce
21 1.20K $246.31K 0.17%
0.17%
Hold
22 6.00K $243.12K 0.17%
0.17%
Hold
23 15.00K $242.93K 0.17%
0.17%
Reduce
24 2.00K $242.70K 0.17%
0.17%
Reduce
25 20.00K $241.20K 0.17%
0.17%
Hold
26 7.00K $236.46K 0.16%
0.16%
Reduce
27 9.00K $234.00K 0.16%
0.16%
Reduce
28 692 $230.13K 0.16%
0.16%
Hold
29 1.00K $227.83K 0.16%
0.16%
Reduce
30 12.00K $225.60K 0.15%
0.15%
Reduce
31 2.00K $223.58K 0.15%
0.15%
Reduce
32 2.50K $220.12K 0.15%
0.15%
Hold
33 15.00K $214.80K 0.15%
0.15%
Reduce
34 2.50K $213.70K 0.15%
0.15%
Hold
35 7.00K $212.03K 0.14%
0.14%
Reduce
36 1.50K $211.34K 0.14%
0.14%
Reduce
37 5.00K $203.00K 0.14%
0.14%
Hold
38 13.00K $175.11K 0.12%
0.12%
Hold
39 10.00K $161.10K 0.11%
0.11%
Reduce
40 10.00K $124.40K 0.09%
0.09%
Reduce
41 15.00K $115.05K 0.08%
0.08%
Hold
42 39.40K $107.17K 0.07%
0.07%
Hold
43 30.00K $102.60K 0.07%
0.07%
Reduce
44 10.00K $86.40K 0.06%
0.06%
Hold

Holdings Prediction Model

Predicts next-quarter Top-10 holdings and weights from the fund's own historical trading轨迹 (add / reduce / hold) plus each stock's price momentum and relative volume. Strictly no look-ahead: a prediction for quarter T+1 uses only data through quarter T. Weights are shares of the modelled portfolio.

The next-quarter predicted Top 10 (2026-Q4) is shown in the «Latest Q · Forecast» tab above, in the same holdings format. That view is for logged-in accounts: 3 views per day on Free, unlimited on Gold/Diamond.

Latest-Quarter Accuracy (2026-Q3)

P 60% R 60% F1 60% (modelled on 2026-Q2; 6/10 hit)

Low-confidence forecast This fund replaces about 60% of its Top-10 each quarter and backtests at F1 40% (threshold 80%). Holdings in high-turnover portfolios cannot be forecast from their own history; the figures below are illustrative.

Historical Backtest (2 quarters)

Avg precision 40% · recall 40% · F1 40% · avg rank error 4.0 · Top-10 turnover 60%

Quarter Prec. Recall F1 Predicted Top 10 Actual Top 10
2026-Q2 20% 20% 20% SGOV · XBI · SERA · DFTX · TYRA · ASND · PHVS · CYTK · HALO · KYMR XBI · SGOV · RPRX · NRIX · INCY · ARGX · IRON · RAPP · RARE · TRVI
2026-Q3 ★ 60% 60% 60% XBI · SGOV · INCY · RPRX · ARGX · NRIX · RAPP · IRON · TRVI · HALO SGOV · XBI · SERA · HALO · MDGL · EXEL · RPRX · ARGX · NRIX · TGTX

★ = latest filed quarter (predicted vs actual). Recall = share of the real Top 10 caught by the model; precision = share of the predicted Top 10 that were real.

FAQ

What did PSP Research LLC buy in 2026-Q3?

In its 2026-Q3 13F filing, PSP Research LLC reported 44 equity positions worth $145.83M in aggregate; its largest disclosed positions were SGOV ($70.48M), XBI ($60.94M), SERA ($5.01M).

How large is PSP Research LLC's portfolio?

PSP Research LLC reported $145.83M of long equity holdings across 44 positions as of 2026-Q3. Top-10 holdings account for 95.0% of reported value.

What is PSP Research LLC's investment style?

HoldingsHub classifies the portfolio as Small / Focused / High Turnover, computed from size, concentration, sector tilt and turnover.

Where does this data come from?

All figures are computed from the fund's SEC Form 13F quarterly filing, which must be filed within 45 days of quarter end for long positions of $100,000 or more.

Embed this fund on your site

Copy the snippet below to show this fund's live top holdings on your blog or forum — free, auto-updating, links back to HoldingsHub.

<iframe src="https://holdingshub.top/funds/psp-research/widget" width="100%" height="520" frameborder="0" loading="lazy" title="HoldingsHub fund holdings"></iframe>

Preview the embeddable widget →